- Must have completed the double-blind portion of the preceding trial
- Completed any protocol specified withdrawal phase and follow-up visits.
- Patient cannot participate if they experienced a serious adverse event or a
nonserious, but medically significant adverse event during the preceding efficacy
study that was judged to be related to the study medication.